Ubiquigent Limited, a Dundee, Scotland, UK-based company specializing in ubiquitin cell-signalling system drug discovery capabilities and services, raised £500k in funding.
Backers included IP Group plc and the Scottish Investment Bank, the investment arm of Scottish Enterprise.
The company intends to use the funds to accelerate the development and commercialization of these drug discovery platforms.
Led by Dr Jason Brown, Managing Director, Ubiquigent develops and provides a range of reagents, kits, assay development, drug lead compound profiling (including DUBprofiler for profiling deubiquitylase enzyme inhibitors) and other services. These products and services support academic and pharmaceutical researchers to understand the role of protein ubiquitylation in regulating many aspects of cellular functions and the development and optimization of drug candidate compounds that target the system addressing a number of critical therapeutic areas.
The company, which is located at the University of Dundee and with direct access to the scientific expertise of the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU), also added pharmaceutical industry veteran Dr Mark Treherne to its board as a Non-Executive Director.
FinSMEs
18/09/2013